



61

AF 1644

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

| | |
|------------------------|------------------|
| Application Number | 09/688,017 |
| Filing Date | October 13, 2000 |
| First Named Inventor | Unger, Marc |
| Art Unit | 1644 |
| Examiner Name | DeCloux, Amy M. |
| Attorney Docket Number | 020054-001110US |

Total Number of Pages in This Submission

ENCLOSURES (Check all that apply)

| | | |
|---|--|---|
| <input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) | <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure (please identify below) Return Postcard, copy of fifty-seven (57) cited references |
|---|--|---|

RECEIVED

FEB 05 2004

TECH CENTER 1000/2900

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

| | |
|--------------------|--|
| Firm or Individual | Townsend and Townsend and Crew LLP Scott L. Ausenhus Reg. No. 42,271 |
| Signature | |
| Date | January 28, 2004 |

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

| | | | |
|-----------------------|-------------------|------|------------------|
| Typed or printed name | Nicole M. Wartell | | |
| Signature | | Date | January 28, 2004 |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.




I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 020054-001110US

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On January 28, 2004

TOWNSEND and TOWNSEND and CREW LLP

By: 
Nicole M. Burke

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

FEB 08 2004

In re application of:

LU et al.

Application No.: 09/688,017

Filed: October 13, 2000

For: MOLECULAR INTERACTIONS
IN HEMATOPOIETIC CELLS

Examiner: DeCloux, Amy M.

Art Unit: 1644

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

TECH CENTER 1600/2900

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicants wish to make the Examiner aware of the following co-pending patent applications:

1. U.S. Patent App. No. 09/722,069, filed 11/24/2000, Attorney Docket No. 020054-001122US; and
2. U.S. Patent App. No. 09/724,553, filed 11/28/2000, Attorney Docket No. 020054-001130US.

To comply with 37 CFR §1.98(a)(2)(iii), the specifications, claims and drawings for the above applications are enclosed.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Scott L. Ausenhus
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 303-571-4000
Fax: 303-571-4321
SLA:nmb



PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 1 of 5

Complete if Known

| | |
|------------------------|-----------------------|
| Application Number | 09/688,017 |
| Filing Date | October 13, 2000 |
| First Named Inventor | Lu, Peter S., et. al. |
| Art Unit | 1644 |
| Examiner Name | DeCloux, Amy M. |
| Attorney Docket Number | 020054-001110US |

U.S. PATENT DOCUMENTS

| Examiner | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|----------|-----------------------|--|--------------------------------|--|---|
| | | Number Kind Code ² (if known) | | | |
| | A1 | US-5,632,994 | 05/27/97 | Reed et al. | |
| | A2 | US-5,747,245 | 05/05/98 | Reed et al. | |
| | A3 | US-5,876,939 | 03/02/99 | Reed et al. | |
| | A4 | U.S. Application No. 07/724,553 | | Lu et al. | |
| | A5 | U.S. Application No. 09/722,069 | | Lu et al. | |

RECEIVED

FEB 03 2004

TECH CENTER 10/13/2000

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|-----------------------|--------------------------|---------------------------|---------------------|-----------------------------------|--------------------------------|---|--|--------------------------|
| | | Country Code ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | B1 | PCT | WO 98/05347 | A1 | 02-12-1998 | | | <input type="checkbox"/> |
| | B2 | PCT | WO 98/23781 | A1 | 06-04-1998 | | | <input type="checkbox"/> |
| | B3 | PCT | WO 98/40407 | A1 | 09-17-1998 | | | <input type="checkbox"/> |
| | B4 | PCT | WO 99/03974 | A1 | 01-28-1999 | | | <input type="checkbox"/> |
| | B5 | PCT | WO 99/07846 | A1 | 02-18-1999 | | | <input type="checkbox"/> |
| | B6 | PCT | WO 00/15794 | A1 | 03-23-2000 | | | <input type="checkbox"/> |
| | B7 | PCT | WO 00/31124 | A2 | 06-02-2000 | | | <input type="checkbox"/> |
| | B8 | PCT | WO 00/48002 | A1 | 08-17-2000 | | | <input type="checkbox"/> |
| | B9 | PCT | WO 00/69896 | A2 | 11-23-2000 | Arbor Vita Corp | | <input type="checkbox"/> |
| | B10 | PCT | WO 00/69897 | A2 | 11-23-2000 | Arbor Vita Corp | | <input type="checkbox"/> |
| | B11 | PCT | WO 00/69898 | A2 | 11-23-2000 | Arbor Vita Corp | | <input type="checkbox"/> |
| | B12 | PCT | WO 02/42422 | A2 | 05-30-2002 | Arbor Vita Corp | | <input type="checkbox"/> |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | | | |
|---|---|--------------------------|-----------------------|------------------------|-----------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 09/688,017 | | |
| | | Filing Date | October 13, 2000 | | |
| | | First Named Inventor | Lu, Peter S., et. al. | | |
| | | Art Unit | 1644 | | |
| | | Examiner Name | DeCloux, Amy M. | | |
| Page | 2 | of | 5 | Attorney Docket Number | 020054-001110US |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C1 ✓ | Altin, J. and Sloan, E. "The role of CD45 and CD45-associated molecules in T cell activation" <i>Immunology and Cell Biology</i> , 1997, pp. 430-445, Vol. 75. | |
| | C2 ✓ | Bals, R. et al. "Augmentation of Innate Host Defense by Expression of a Cathelicidin Antimicrobial Peptide", <i>Infection and Immunity</i> , November 1999, pp. 6084-6089, Vol. 67, No. 11. | |
| | C3 ✓ | Barclay, A., et al., "The Leukocyte Antigen Factsbook", <i>Harcourt Braces & Company</i> , page 363, (1997). | |
| | C4 ✓ | Bruyns, E. et al. "Identification of the Sites of Interaction between Lymphocyte Phosphatase-associated Phosphoprotein (LPAP) and CD45", <i>Journal of Biological Chemistry</i> , December 29, 1996, pp. 31372-31376, Vol. 270, No. 52, U.S.A. | |
| | C5 ✓ | Cherukuri, A. et al. "Floating the raft hypothesis: lipid rafts play a role in immune cell activation", <i>Immunity</i> , June 2001, pp.657-660, Vol. 14, Cell Press. | |
| | C6 ✓ | Ding, I. Et al., "Biochemical and Functional Analysis of Mice Deficient in Expression of the CD45-Associated Phosphoprotein LPAP", <i>European Journal of Immunology</i> , 29(12):3956-61 (1999) | |
| | C7 ✓ | Doyle, D. A., et al., "Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ", <i>Cell</i> , 85(7):1067-76, (1996). | |
| | C8 ✓ | Faulkner, G. et al. "A New Z-band Alternatively Spliced PDZ-motif Protein." <i>The Journal of Cell Biology</i> , July 26, 1999; pp. 465-475, Vol. 146, No. 2. | |
| | C9 ✓ | Gardioli, D. et al. "Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation", <i>Oncogene</i> , 18(40):5487-5496, (1999). | |
| | C10 ✓ | Gee, S.H., et al., "Cyclic Peptides as Non-carboxyl-terminal Ligands of Syntrophin PDZ Domains", <i>The Journal of Biological Chemistry</i> , 273(34):21980-21987, (1998). | |
| | C11 ✓ | Hanada, T., et al., "Human Homologue of the Drosophila Discs Large Tumor Suppressor Binds to p56 ^{lck} Tyrosine Kinase and Shaker Type Kv1.3 Potassium Channel in T. Lymphocytes", <i>The Journal of Biological Chemistry</i> , 272(43):26899-26904, (1997). | |
| | C12 ✓ | Kiyono, T. et al. "Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein", <i>Proc. Natl. Acad. Sci.</i> , October 1997, pp. 11612-11616, Vol. 94, U.S.A. | |
| | C13 ✓ | Kobayashi, I., et al., "Identification of an Autoimmune Enteropathy-related 75-kilodalton Antigen", <i>Gastroenterology</i> , October 1999, pp. 823-830, Vol. 117, No. 4. | |

RECEIVED

FEB 08 2004

TECH CENTER 1600/2900

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 3 of 5

Complete if Known

| | |
|------------------------|-----------------------|
| Application Number | 09/688,017 |
| Filing Date | October 13, 2000 |
| First Named Inventor | Lu, Peter S., et. al. |
| Art Unit | 1644 |
| Examiner Name | DeCloux, Amy M. |
| Attorney Docket Number | 020054-001110US |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|------------------------|--------------------------|---|----------------|
| | C14 | Maekawa, K., et al., "Association of Protein-Tyrosine Phosphatase PTP-BAS with the Transcription-factor-inhibitory Protein IxB α Through Interaction Between the PDZ1 Domain and Ankyrin Repeats", <i>Biochemical Journal</i> , 337(2):179-187, (1999). | |
| | C15 | McKusick, Victor A.; OMIM Database entry entitled, '147138 Fc Fragment of IgE, High Affinity I, Receptor for, Beta Subunit; FCER1B', www.ncbi.nlm.nih.gov/htbin-post/Omim/dispmm?147138, 08/27/1992. | |
| | C16 | Nagase, T. et al. "Prediction of the Coding Sequence of Unidentified Human Genes. V1. The Coding Sequences of 80 New Genes (KIAA0201-KIAA0280) Deduced by Analysis of cDNA Clones from Cell Line KG-1 and Brain", <i>DNA Research</i> , 1996, pp. 321-329, Vol. 3. | |
| | C17 | Nagase, T. et al. "Prediction of the Coding Sequence of Unidentified Human Genes. V1. The Coding Sequences of 80 New Genes (KIAA0201-KIAA0280) Deduced by Analysis of cDNA Clones from Cell Line KG-1 and Brain (Supplement)", <i>DNA Research</i> , 1996, pp. 341-354, Vol. 3, Supplement. | |
| | C18 | Nishihara, H. et al. "Non-adherent cell-specific expression of DOCK2, a member of the human CDM-family proteins", <i>Biochimica et Biophysica Acta</i> , 1999, pp. 179-187, Elsevier Publishing. | |
| | C19 | Nishihara, H. "Analysis of Hematopoietic Cell Specific Protein, M-DOCK", <i>Hokkaido Igaku Zasshi</i> , March 1999, p. 157-166, Vol. 74, No. 2. | |
| | C20 | Patel, V. et al., "A Molecular Framework for 2-Step T Cell Signaling: Lck Src Homology 3 Mutations Discriminate Distinctly Regulated Lipid Raft Reorganization Events", <i>Journal of Immunology</i> , 166(2):754-64 (2001). | |
| | C21 | Rasooly, Rebekah S.; OMIM Database entry entitled, "603122 Dedicator of Cytokinesis 2; Dock 2" www.ncbi.nlm.nih.gov/htbin-post/Omim/dispmm?603122, 10/12/1998. | |
| | C22 | Reynaud, C. et al., "The PDZ Protein TIP-1 Interacts with the Rho Effector Rhotekin and Is Involved in Rho Signaling to the Serum Response Element", <i>The Journal of Biological Chemistry</i> , 275(43):33962-33968, (2000). | |
| | C23 | Rousset, R., et al., "The C-terminus of the HTLV-1 Tax oncoprotein mediates interaction with the PDZ domain of cellular proteins" <i>Oncogene</i> , 16(5):643-54, (1998). | |
| | C24 | Saras, J., et al., "PDZ Domains Bind Carboxy-Terminal Sequences of Target Proteins", <i>Tibs Trends in Biochemical Sciences</i> , en, Elsevier Publication, Cambridge, 21(12):455-458, (1996). | |

RECEIVED

FEB 08 2004

TECH CENTER 1000/2900

| | |
|-----------------------|--------------------|
| Examiner Signature | Date Considered |
|-----------------------|--------------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 4 of 5

Complete if Known

| | |
|------------------------|-----------------------|
| Application Number | 09/688,017 |
| Filing Date | October 13, 2000 |
| First Named Inventor | Lu, Peter S., et. al. |
| Art Unit | 1644 |
| Examiner Name | DeCloux, Amy M. |
| Attorney Docket Number | 020054-001110US |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|------------------------|--------------------------|---|----------------|
| | C25 | Schepens, J., et al., "The Neuronal Nitric Oxide Synthase PDZ Motif Binds to -G(D.E)XV Carboxy Terminal Sequences", <i>Febs Letters</i> , 409(1-2):53-56, (1997). | |
| | C26 | Schraven, Burkhardt et al. "LPAP, a Novel 32-kDa Phosphoprotein That Interacts With CD45 in Human Lymphocytes", <i>J. Biological Chemistry</i> , Nov. 18, 1994; pp. 29102-29111, Vol. 269, No. 46. | |
| | C27 | Shibuya, A., et al., "DNAM-1, A Novel Adhesion Molecule Involved in the Cytolytic Function of T Lymphocytes", <i>Immunity</i> , 4:573-581, (1996). | |
| | C28 | Shibuya, A., et al., "Protein Kinase C is Involved in the Regulation of Both Signaling and Adhesion Mediated by DNAX Accessory Molecule-1 Receptor", <i>The Journal of Immunology</i> , 161:1671-1676, (1998). | |
| | C29 | Shibuya, K., et al., "Physical and Functional Association of LFA-1 with DNAM-1 Adhesion Molecule", <i>Immunity</i> , 11:615-623, (1999). | |
| | C30 | Suzuki, T., et al., "Tax oncoprotein of HTLV-1 binds to the human homologue of Drosophila discs large tumor suppressor protein, hDLG, and perturbs its function in cell growth control", <i>Oncogene</i> , 18(44):5967-72, (1999). | |
| | C31 | Vallénus, T. et al. "CLP-36 PDZ-LIM Protein Associates with Nonmuscle alpha-Actinin-1 and alpha-Actinin-4." <i>The Journal of Biological Chemistry</i> , April 14, 2000; pp. 11100-11105, Vol. 275, No. 15. | |
| | C32 | Wechsler, A. et al. "Brain Spectrin binding to the NMDA receptor is regulated by phosphorylation, calcium and calmodulin." <i>The EMBO Journal</i> , 1998, pp. 3931-3939, Vol. 17, No. 14. | |
| | C33 | Xia, H. et al. "Actinin-associated LIM Protein: Identification of a Domain Interaction between PDZ and Spectrin-like Repeat Motifs", <i>The Journal of Cell Biology</i> , October 1997, pp. 507-515, Vol. 139, No. 2. | |
| | C34 | Yanagisawa, J., et al., "The Molecular interaction of Fas and FAP-1. A tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis", <i>J. Biol. Chem.</i> , 272(13):8539-8545, (1997). | |
| | C35 | GenBank, Accession Number AF028823, 12/01/1999 | |
| | C36 | GenBank, Accession Number BM845132, 03/06/2002 | |
| | C37 | GenBank, Accession Number CB131761, 01/29/2003 | |
| | C38 | GenBank, Accession Number CB961389, 04/28/2003 | |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

47111948 v1



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 5 of 5

Complete if Known

| | |
|------------------------|------------------------|
| Application Number | 09/688,017 |
| Filing Date | October 13, 2000 |
| First Named Inventor | Lu, Peter S. , et. al. |
| Art Unit | 1644 |
| Examiner Name | DeCloux, Amy M. |
| Attorney Docket Number | 020054-001110US |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|------------------------|--------------------------|---|----------------|
| | C39 ✓ | GenBank, Accession Number CB995033, 04/30/2003 | |
| | C40 ✓ | Genbank, Accession Number D86964, 02/07/1999 | |

RECEIVED

FEB 06 2004

TECH CENTER 1600/2900

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.